ISSN: 2754-6667

Journal of Critical Care & Emergency Medicine

SCIENTIFIC Research and Community

Review Article

Open Access

Kidney Replacement Therapy in a Shocked Brain: CRRT or IHD: Who's the Real Brain-Saver in the Dialysis Arena?

Ibrahim F

Anaesthesia and Critical Care Department King Abdulaziz University Hospital Jeddah, Saudi Arabia

***Corresponding author**
Ibrahim F, Anaesthesia and Critical Care Department King Abdulaziz University Hospital Jeddah, Saudi Arabia.

Received: October 20, 2025; **Accepted:** October 24, 2025; **Published:** March 31, 2026

Introduction

The Brain-Kidney Battlefield

Acute brain injury disrupts the Blood-Brain Barrier (BBB), impairs autoregulation, and leads to cerebral oedema and Increased Intracranial Pressure (ICP). ABI can be Traumatic (TBI, SAH) or Non-Traumatic (AIS, ICH), and studies show that up to 89% of these patients develop dysfunction in at least one non-neurological organ—most notably the kidneys.

Even young patients with previously normal renal function face an AKI incidence of 8–23%, which significantly increases morbidity, mortality, and the risk of tentorial herniation. In older patients with AIS or ICH, AKI incidence rises to 14–21%, compounded by comorbidities.

Taming the Double-Edged Sword

Kidney Replacement Therapy (KRT) is a powerful ally in the ICU—capable of reversing life-threatening metabolic derangements and supporting organ recovery. But in neurocritical patients, especially those with Acute Brain Injury (ABI), the timing and modality of KRT can make or break outcomes. When applied without precision, KRT can destabilize cerebral perfusion, trigger osmotic shifts, and transform a therapeutic tool into a neurological threat.

Pathophysiology

The Brain-Kidney Crosstalk

Bidirectional Injury

AKI and ABI feed into each other. Inflammatory mediators, uremic toxins, and autonomic dysregulation create a vicious cycle:

- Cytokines damage both BBB and renal tubules.
- Uremic toxins increase BBB permeability and worsen cerebral edema.
- Sympathetic overactivation leads to renal vasoconstriction, reduced GFR, and RAAS activation.

Iatrogenic Contributors

- Contrast media, especially intra-arterial, increases AKI risk.
- Hyperosmolar therapies like mannitol and hypertonic saline can paradoxically worsen renal function.
- Nephrotoxic antibiotics (vancomycin, aminoglycosides).
- KRT itself, particularly IHD, can trigger dialysis disequilibrium syndrome (DDS) and intradialytic hypotension.

Critical Inquiries

To Dialyse or Not to Dialyse: The Neurocritical Question

Why Start Dialysis?

- Prevent secondary brain injury from fluid overload, acidosis, and electrolyte imbalances.
- Uraemia impairs platelet function and increases BBB permeability.
- Metabolic acidosis increases cerebral blood flow, worsening ICP.

The Real Danger: Dialysis in ABI

Osmotic Shifts

Rapid urea removal during IHD creates an osmotic gradient that draws water into the brain—classic DDS. Even in chronic ESRD patients, ABI changes the game:

- Idiogenic osmoles in injured brain tissue create reverse osmotic shifts.
- BBB breakdown makes the brain more vulnerable to fluid shifts.
- Rapid correction of acidosis may paradoxically worsen cerebral edema.

Hemodynamic Instability

In ABI, cerebral perfusion pressure (CPP) depends on mean arterial pressure (MAP). IHD-induced hypotension lowers CPP, risking ischemia and passive hyperaemia.

Brain-Protective KRT Strategies

Where Renal Rescue Meets Neuro Respect

Modality Matters

- CRRT is preferred for its slow, continuous clearance.
- SLEED offers a middle ground—low-efficiency IHD with better ICP control.
- Pre-dilution hemofiltration is intentionally less efficient at urea clearance, which is beneficial in ABI.

Timing is Brain

- Avoid dialysis in the first 24h post-ABI unless urgently needed.
- Start before BUN rises drastically—target <30 mg/dL.
- Daily treatments reduce osmotic fluctuations.

Fluid Composition

- Sodium: Use higher concentrations (145–150 mmol/L) to prevent osmotic shifts.
- Urea: Add to dialysate to reduce the diffusion gradient.
- Bicarbonate: Lower concentrations (25–30 mmol/L) to avoid paradoxical cerebral acidosis.
- Calcium: Higher levels support cardiovascular and neuromuscular stability.

Temperature Control

Cool dialysate helps reduce cerebral metabolic demand and stabilize ICP.

Ultrafiltration

Slow, low-volume UF prevents intradialytic hypotension and protects CPP.

Dialyzer Size

Smaller surface area filters slow solute clearance, reducing osmotic stress.

Anticoagulation

- Regional Citrate Anticoagulation (RCA) is preferred.
- Avoid systemic anticoagulants due to bleeding risk.

Flow Rates

Start with low blood (100–150 ml/min) and dialysate flow rates. Increase gradually to avoid rapid solute shifts.

Putting It All Together: One Brain, One Kidney, One Chance

Feature	Brain-Protective Strategy	Rationale
Modality	CRRT > SLEED > IHD	Minimize osmotic and hemodynamic shifts
Timing	Delay 24h if possible; start early before BUN rises	Prevent DDS and ICP spikes
Access	Prefer femoral vein	Avoid jugular compression
Flow Rates	Start low, increase slowly	Reduce solute clearance stress
Dialysate Composition	High Na^+, low HCO_3^-, add urea	Prevent osmotic shifts and cerebral acidosis
UF Strategy	Low volume, slow rate	Maintain CPP
Anticoagulation	RCA preferred	Minimize bleeding risk
Temperature	Match therapeutic goals	Stabilize brain metabolism
Dialyzer Size	Smaller surface area	Reduce solute clearance rate

Conclusion

Dial Slow, Think Fast

KRT in ABI patients is a high-stakes balancing act. The goal isn't just to clear toxins—it's to protect the brain. By customizing modality, timing, fluid composition, and flow rates, we transform dialysis from a potential threat into a neuroprotective strategy. In the ICU, where every minute and molecule matters, brain-protective dialysis isn't just smart—it's essential [1-10].

References

1. Griffin BR, Liu KD, Teixeira JP (2020) Critical Care Nephrology: Core Curriculum 2020. Am J Kidney Dis 75: 435-452.
2. Kellum JA, Ronco C, Bellomo R (2021) Conceptual advances and evolving terminology in acute kidney disease. Nat Rev Nephrol 17: 493-502.
3. James MT, Bhatt M, Pannu N, Tonelli M (2020) Long-term outcomes of acute kidney injury and strategies for improved care. Nat Rev Nephrol 16: 193-205.
4. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute Dialysis Quality Initiative workgroup. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204-212.
5. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, et al. (2007) Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31.
6. (2012) Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2: 1-138.
7. Vanmassenhove J, Steen J, Vansteelandt S, Morzywolek P, Hoste E, et al. (2021) The importance of the urinary output criterion for the detection and prognostic meaning of AKI. Sci Rep 11: 11089.
8. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, et al. (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41: 1411-1423.
9. Ramirez-Guerrero G, Lucero C, Villagran-Cortes F, Hauway E, Torres- Cifuentes V, et al. (2023) Acute kidney injury in neurocritical patients: a retrospective cohort study. Int Urol Nephrol 55: 1875-1883.
10. Robba C, Banzato E, Rebora P, Iaquaniello C, Huang CY, et al. (2021) Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (TBI) ICU Participants and Investigators. Acute kidney injury in traumatic brain injury patients: results from the collaborative European neurotrauma effectiveness research in traumatic brain injury study. Crit Care Med 49: 112-126.